ophthalmologyОфтальмологияOphthalmology in Russia1816-50952500-0845Ophthalmology10.18008/1816-5095-2022-1-22-32ophthalmology-1766Research ArticleОБЗОРЫREVIEWSАнализ результатов проведения клинических исследований при неоваскулярной возрастной макулярной дегенерации за 2005–2020 гг. Обзор литературыAnalysis of Clinical Study Results Obtained in Patients with Neovascular Age-Related Macular Degeneration in 2005–2020. Reviewhttps://orcid.org/0000-0003-0368-296XГавриловаН. А.GavrilovaN. A.

Гаврилова Наталья Александровна, доктор медицинских наук, профессор, зав. кафедрой глазных болезней

ул. Делегатская, 20, стр. 1, Москва, 127473

Gavrilova Natalia A., MD, Professor

Delegatskaya str., 20, p. 1, Moscow, 127473

https://orcid.org/0000-0002-4197-1984ГаджиеваН. С.GadzhievaN. S.

Гаджиева Нурия Саниевна, кандидат медицинских наук, доцент кафедры глазных болезней

ул. Делегатская, 20, стр. 1, Москва, 127473

Gadzhieva Nuria S., PhD, Assistant Professor

Delegatskaya str., 20, p. 1, Moscow, 127473

https://orcid.org/0000-0001-8777-0275ТищенкоО. Е.TishchenkoO. E.

Тищенко Ольга Евгеньевна, кандидат медицинских наук, доцент кафедры глазных болезней

ул. Делегатская, 20, стр. 1, Москва, 127473

Tishchenko Ol’ga E., PhD, Assistant Professor

Delegatskaya str., 20, p. 1, Moscow, 127473

https://orcid.org/0000-0003-4373-3135ЗиновьеваА. В.Zinov’evaA. V.

Зиновьева Александра Витальевна, старший лаборант кафедры глазных болезней

ул. Делегатская, 20, стр. 1, Москва, 127473

Zinov’eva Aleksandra V., senior laboratory assistant

Delegatskaya str., 20, p. 1, Moscow, 127473

aleksandra.r@live.ruФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Министерства здравоохранения Российской ФедерацииРоссияA.I. Yevdokimov Моscow State University of Medicine and DentistryRussian Federation2022060420221912232Copyright © Гаврилова Н.А., Гаджиева Н.С., Тищенко О.Е., Зиновьева А.В., 20222022Гаврилова Н.А., Гаджиева Н.С., Тищенко О.Е., Зиновьева А.В.Gavrilova N.A., Gadzhieva N.S., Tishchenko O.E., Zinov’eva A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.ophthalmojournal.com/opht/article/view/1766

В настоящее время неоваскулярная форма возрастной макулярной дегенерации (ВМД) является одной из основных причин слепоты и инвалидности по зрению. Несмотря на установленную ключевую роль семейства белков сосудистого фактора роста (vascular endothelial growth factor, VEGF) в регуляции ангиогенеза и вазопроницаемости, точный патогенетический механизм неоваскулярной ВМД остается не до конца изученным и представляет собой сложный каскад, состоящий из широкого спектра молекул, которые могут быть рассмотрены в качестве потенциальных мишеней для лекарственной терапии. В многочисленных клинических исследованиях последних лет исследовались безопасность и эффективность моно- и комбинированной терапии с использованием новых препаратов в зависимости от их дозы и способа введения. В литературном обзоре авторами представлен анализ результатов проведения клинических исследований по применению генетических препаратов на основе вирусных систем доставки и малых интерферирующих РНК, препаратов-антагонистов факторов роста, ингибиторов ферментативной активности клеточных рецепторов при неоваскулярной форме ВМД. Основная информация о препаратах, разработчиках, фазах клинических испытаний и результатах представлена в виде таблиц. Полученные результаты исследований позволяют судить о том, что таргетная терапия неоваскулярной ВМД остается перспективным направлением для проведения дальнейших исследований.

Currently, there is a wide range of antiglaucoma drugs. Ophthalmologists are faced with the task of choosing certain drugs and their combinations for specific patients. In this regard, studies aimed at studying the effectiveness of treatment, not only in terms of IOP indicators and instrumental research methods, but also in terms of the choice of a particular type of therapy by ophthalmologists, are of great interest. Purpose: to analyze the data obtained in the course of the study of the Russian multicenter scientific program: “Analysis of the assortability of ophthalmologists when choosing therapy within the framework of routine medical care in patients with primary open-angle glaucoma (POAG)”. The large-scale statistical study carried out was based on the study of 197 medical questionnaires from 61 cities of Russia, containing information on 6851 clinical cases. Doctors were asked to fill out a questionnaire based on the results of treatment (at least 2 months), taking into account the following criteria: satisfaction with treatment, adherence to treatment, accessibility, tolerability and ease of use of drugs. Evaluated the use of 5 antiglaucoma drugs of the company Sentiss Russ, belonging to different pharmacological groups: Prolatan (latanoprost), Bimatan (bimatoprost), Brinex-M (brinzolamide); Tisoptan (bimatoprost / timolol maleate), Brinarga (brinzolamide / timolol maleate). During the study, patients were divided into 6 groups depending on the drug used, and also into 3 groups depending on the stage of primary POAG. The data obtained indicate a statically high level of average values when using the point system of all the above criteria when using these drugs. When analyzing the degree of convenience and the level of tolerance of drugs, a tendency towards a decrease in the average scores of these indicators in patients with advanced stage of glaucoma was noted, which may be due to the long-term use of antiglaucoma therapy in this category of patients with changes in the ocular surface. 98.25% of doctors expressed their intention to continue prescribing antiglaucoma drugs from Sentiss Russ.

VEGFнеоваскулярная ВМДгенная терапияанти-VEGFsiRNAVEGFneovascular AMDgene therapyanti-VEGFsiRNAReferencesFernández-Robredo P., Sancho A., Johnen S., Recalde S., Gama N., Thumann G., Groll J., García-Layana A. Current treatment limitations in age-related macular degeneration and future approaches based on cell therapy and tissue engineering. J Ophthalmol. 2014;2014:510285. DOI: 10.1155/2014/510285Fernández-Robredo P., Sancho A., Johnen S., Recalde S., Gama N., Thumann G., Groll J., García-Layana A. Current treatment limitations in age-related macular degeneration and future approaches based on cell therapy and tissue engineering. J Ophthalmol. 2014;2014:510285. DOI: 10.1155/2014/510285Daniel E., Toth C.A., Grunwald J.E., Jaffe G.J., Martin D.F., Fine S.L., Huang J., Ying G., Hagstrom S.A., Winter K., Maguire M.G. Risk of scar in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2014;121(3):656–666. DOI: 10.1016/j.ophtha.2013.10.019Daniel E., Toth C.A., Grunwald J.E., Jaffe G.J., Martin D.F., Fine S.L., Huang J., Ying G., Hagstrom S.A., Winter K., Maguire M.G. Risk of scar in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2014;121(3):656–666. DOI: 10.1016/j.ophtha.2013.10.019Lally D.R., Gerstenblith A.T., Regillo C.D. Preferred therapies for neovascular agerelated macular degeneration. Current Opinion in Ophthalmology. 2012;23(3):182–188. DOI: 10.1097/ICU.0b013e328352411cLally D.R., Gerstenblith A.T., Regillo C.D. Preferred therapies for neovascular agerelated macular degeneration. Current Opinion in Ophthalmology. 2012;23(3):182–188. DOI: 10.1097/ICU.0b013e328352411cKim M., Kim E.S., Seo K.H., Yu S.Y., Kwak H.W. Change of retinal pigment epithelial atrophy after anti-vascular endothelial growth factor treatment in exudative age-related macular degeneration. Indian J Ophthalmol. 2016;64(6):427–433. DOI: 10.4103/0301-4738.187659Kim M., Kim E.S., Seo K.H., Yu S.Y., Kwak H.W. Change of retinal pigment epithelial atrophy after anti-vascular endothelial growth factor treatment in exudative age-related macular degeneration. Indian J Ophthalmol. 2016;64(6):427–433. DOI: 10.4103/0301-4738.187659Yang S., Zhao J., Sun X. Resistance to anti-VEGF therapy in neovascular agerelated macular degeneration: a comprehensive review. Drug Des Devel Ther. 2016;10:1857–1867. DOI: 10.2147/DDDT.S97653Yang S., Zhao J., Sun X. Resistance to anti-VEGF therapy in neovascular agerelated macular degeneration: a comprehensive review. Drug Des Devel Ther. 2016;10:1857–1867. DOI: 10.2147/DDDT.S97653Campochiaro P.A. Nguyen Q.D., Shah S.M., Klein M.L., Holz E., Frank R.N., Saperstein D.A., Gupta A., Stout J.T., Macko J., DiBartolomeo R., Wei L.L. Adenoviral vectordelivered pigment epithelium-derived factor for neovascular agerelated macular degeneration: results of a phase I clinical trial. Hum Gene Ther. 2006;17(2):167–176.Campochiaro P.A. Nguyen Q.D., Shah S.M., Klein M.L., Holz E., Frank R.N., Saperstein D.A., Gupta A., Stout J.T., Macko J., DiBartolomeo R., Wei L.L. Adenoviral vectordelivered pigment epithelium-derived factor for neovascular agerelated macular degeneration: results of a phase I clinical trial. Hum Gene Ther. 2006;17(2):167–176.Constable I.J., Lai C.M., Magno A.L., French M.A., Barone S.B., Schwartz S.D., Blumenkranz M.S., Degli-Esposti M.A., Rakoczy E.P. Gene Therapy in Neovascular Agerelated Macular Degeneration: Three-Year Follow-up of a Phase 1 Randomized Dose Escalation Trial. Am J Ophthalmol. 2017;177:150–158. DOI: 10.1016/j.ajo.2017.02.018Constable I.J., Lai C.M., Magno A.L., French M.A., Barone S.B., Schwartz S.D., Blumenkranz M.S., Degli-Esposti M.A., Rakoczy E.P. Gene Therapy in Neovascular Agerelated Macular Degeneration: Three-Year Follow-up of a Phase 1 Randomized Dose Escalation Trial. Am J Ophthalmol. 2017;177:150–158. DOI: 10.1016/j.ajo.2017.02.018Rakoczy E.P., Magno A.L., Lai C.M., Pierce C.M., Degli-Esposti M.A., Blumenkranz M.S., Constable I.J. Three-Year Follow-Up of Phase 1 and 2a rAAV.sFLT-1 Subretinal Gene Therapy Trials for Exudative Age-Related Macular Degeneration. American Journal of Ophthalmology. 2019;204:113–123. DOI: 10.1016/j.ajo.2019.03.006Rakoczy E.P., Magno A.L., Lai C.M., Pierce C.M., Degli-Esposti M.A., Blumenkranz M.S., Constable I.J. Three-Year Follow-Up of Phase 1 and 2a rAAV.sFLT-1 Subretinal Gene Therapy Trials for Exudative Age-Related Macular Degeneration. American Journal of Ophthalmology. 2019;204:113–123. DOI: 10.1016/j.ajo.2019.03.006Heier J.S., Kherani S., Desai S., Dugel P., Kaushal S., Cheng S.H., Delacono C., Purvis A., Richards S., Le-Halpere A., Connelly J., Wadsworth S.C., Varona R., Buggage R., Scaria A., Campochiaro P.A. Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial. Lancet. 2017;390(10089):50–61. DOI: 10.1016/S0140-6736(17)30979-0Heier J.S., Kherani S., Desai S., Dugel P., Kaushal S., Cheng S.H., Delacono C., Purvis A., Richards S., Le-Halpere A., Connelly J., Wadsworth S.C., Varona R., Buggage R., Scaria A., Campochiaro P.A. Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial. Lancet. 2017;390(10089):50–61. DOI: 10.1016/S0140-6736(17)30979-0Campochiaro P.A., Lauer A.K., Sohn E.H., Mir T.A., Naylor S., Anderton M.C., Kelleher M., Harrop R., Ellis S., Mitrophanous K.A. Lentiviral Vector Gene Transfer of Endostatin/Angiostatin for Macular Degeneration (GEM) Study. Hum Gene Ther. 2017;28(1):99–111. DOI: 10.1089/hum.2016.117Campochiaro P.A., Lauer A.K., Sohn E.H., Mir T.A., Naylor S., Anderton M.C., Kelleher M., Harrop R., Ellis S., Mitrophanous K.A. Lentiviral Vector Gene Transfer of Endostatin/Angiostatin for Macular Degeneration (GEM) Study. Hum Gene Ther. 2017;28(1):99–111. DOI: 10.1089/hum.2016.117Cashman S.M., Ramo K., Kumar-Singh R. A non membrane-targeted human soluble CD59 attenuates choroidal neovascularization in a model of age related macular degeneration. PLoS One. 2011;6(4):e19078. DOI: 10.1371/journal.pone.0019078Cashman S.M., Ramo K., Kumar-Singh R. A non membrane-targeted human soluble CD59 attenuates choroidal neovascularization in a model of age related macular degeneration. PLoS One. 2011;6(4):e19078. DOI: 10.1371/journal.pone.0019078Dugel P.U. CLINICAL TRIAL DOWNLOAD: Data on a Gene Therapy for Dry and Wet AMD. A phase 1 clinical trial program is targeting both disease states. Retinal Physician. 2020;17:16–17.Dugel P.U. CLINICAL TRIAL DOWNLOAD: Data on a Gene Therapy for Dry and Wet AMD. A phase 1 clinical trial program is targeting both disease states. Retinal Physician. 2020;17:16–17.Moore N.A., Bracha P., Hussain R.M., Morral N., Ciulla T.M. Gene therapy for agerelated macular degeneration. Expert Opinion on Biological Therapy. 2017;10:1235– 1244. DOI: 10.1080/14712598.2017.1356817Moore N.A., Bracha P., Hussain R.M., Morral N., Ciulla T.M. Gene therapy for agerelated macular degeneration. Expert Opinion on Biological Therapy. 2017;10:1235– 1244. DOI: 10.1080/14712598.2017.1356817Edwards, T.L., Xue, K., Meenink, H.C.M., Beelen M.G., Naus G.J.L., Simunovic M.P., Latasiewicz M., Farmery A.D., de Smet M.D., MacLaren R.E. First-inhuman study of the safety and viability of intraocular robotic surgery. Nat Biomed Eng. 2018;2:649–656. DOI: 10.1038/s41551-018-0248-4Edwards, T.L., Xue, K., Meenink, H.C.M., Beelen M.G., Naus G.J.L., Simunovic M.P., Latasiewicz M., Farmery A.D., de Smet M.D., MacLaren R.E. First-inhuman study of the safety and viability of intraocular robotic surgery. Nat Biomed Eng. 2018;2:649–656. DOI: 10.1038/s41551-018-0248-4Corydon T. J. Antiangiogenic Eye Gene Therapy. Human Gene Therapy. 2015;26(8):525–537. DOI: 10.1089/hum.2015.064Corydon T. J. Antiangiogenic Eye Gene Therapy. Human Gene Therapy. 2015;26(8):525–537. DOI: 10.1089/hum.2015.064Garba A.O., Mousa S.A. Bevasiranib for the treatment of wet, age-related macular degeneration. Ophthalmol Eye Dis. 2010;2:75–83. DOI: 10.4137/OED.S4878Garba A.O., Mousa S.A. Bevasiranib for the treatment of wet, age-related macular degeneration. Ophthalmol Eye Dis. 2010;2:75–83. DOI: 10.4137/OED.S4878Guzman-Aranguez A., Loma P., Pintor J. Small-interfering RNAs (siRNAs) as a promising tool for ocular therapy. Br J Pharmacol. 2013;170(4):730–747. DOI: 10.1111/bph.12330Guzman-Aranguez A., Loma P., Pintor J. Small-interfering RNAs (siRNAs) as a promising tool for ocular therapy. Br J Pharmacol. 2013;170(4):730–747. DOI: 10.1111/bph.12330Kleinman M.E., Yamada K., Takeda A., Chandrasekaran V., Nozaki M., Baffi J.Z., Albuquerque R.J., Yamasaki S., Itaya M., Pan Y., Appukuttan B., Gibbs D., Yang Z., Karikó K., Ambati B.K., Wilgus T.A., DiPietro L.A., Sakurai E., Zhang K., Smith J.R., Taylor E.W., Ambati J. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature. 2008;452(7187):591–597. DOI: 10.1038/nature06765Kleinman M.E., Yamada K., Takeda A., Chandrasekaran V., Nozaki M., Baffi J.Z., Albuquerque R.J., Yamasaki S., Itaya M., Pan Y., Appukuttan B., Gibbs D., Yang Z., Karikó K., Ambati B.K., Wilgus T.A., DiPietro L.A., Sakurai E., Zhang K., Smith J.R., Taylor E.W., Ambati J. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature. 2008;452(7187):591–597. DOI: 10.1038/nature06765Kaiser P.K., Symons R.C., Shah S.M., Quinlan E.J., Tabandeh H., Do D.V., et al. RNAi-based treatment for neovascular age-related macular degeneration by Sirna-027. Am J Ophthalmol. 2010;150:33–39.Kaiser P.K., Symons R.C., Shah S.M., Quinlan E.J., Tabandeh H., Do D.V., et al. RNAi-based treatment for neovascular age-related macular degeneration by Sirna-027. Am J Ophthalmol. 2010;150:33–39.Nguyen Q.D., Schachar R.A., Nduaka C.I., Sperling M., Klamerus K.J., Chi-Burris K., Yan E., Paggiarino D.A., Rosenblatt I., Aitchison R., Erlich S.S.; MONET Clinical Study Group. Evaluation of the siRNA PF-04523655 versus ranibizumab for the treatment of neovascular age-related macular degeneration (MONET Study). Ophthalmology. 2012;119(9):1867–1873. DOI: 10.1016/j.ophtha.2012.03.043Nguyen Q.D., Schachar R.A., Nduaka C.I., Sperling M., Klamerus K.J., Chi-Burris K., Yan E., Paggiarino D.A., Rosenblatt I., Aitchison R., Erlich S.S.; MONET Clinical Study Group. Evaluation of the siRNA PF-04523655 versus ranibizumab for the treatment of neovascular age-related macular degeneration (MONET Study). Ophthalmology. 2012;119(9):1867–1873. DOI: 10.1016/j.ophtha.2012.03.043Corradetti M.N., Inoki K., Guan K.L. The stress-inducted proteins RTP801 and RTP801L are negative regulators of the mammalian target of rapamycin pathway. J Biol Chem. 2005; 280:9769–9772.Corradetti M.N., Inoki K., Guan K.L. The stress-inducted proteins RTP801 and RTP801L are negative regulators of the mammalian target of rapamycin pathway. J Biol Chem. 2005; 280:9769–9772.Dugel P.U., Koh A., Ogura Y., Jaffe G.J., Schmidt-Erfurth U., Brown D.M., Gomes A.V., Warburton J., Weichselberger A., Holz F.G.; HAWK and HARRIER Study Investigators. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2020;127(1):72–84. DOI: 10.1016/j.ophtha.2019.04.017Dugel P.U., Koh A., Ogura Y., Jaffe G.J., Schmidt-Erfurth U., Brown D.M., Gomes A.V., Warburton J., Weichselberger A., Holz F.G.; HAWK and HARRIER Study Investigators. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2020;127(1):72–84. DOI: 10.1016/j.ophtha.2019.04.017Khurana R.N. Abicipar for neovascular age-related macular degeneration: Twoyear results from CEDAR and SEQUOIA phase 3. Presented at: American Academy of Ophthalmology annual meeting; October 11–15, 2019; San Francisco.Khurana R.N. Abicipar for neovascular age-related macular degeneration: Twoyear results from CEDAR and SEQUOIA phase 3. Presented at: American Academy of Ophthalmology annual meeting; October 11–15, 2019; San Francisco.Dugel P.U. CLINICAL TRIAL DOWNLOAD: Data on Abicipar From the MAPLE Study. A new formulation showed reduced inflammation rates. Retinal Physician. 2019;16:18, 42.Dugel P.U. CLINICAL TRIAL DOWNLOAD: Data on Abicipar From the MAPLE Study. A new formulation showed reduced inflammation rates. Retinal Physician. 2019;16:18, 42.Liu K., Song Y., Xu G., Ye J., Wu Z., Liu X., Dong X., Zhang M., Xing Y., Zhu S., Chen X., Shen Y., Huang H., Yu L., Ke Z., Rosenfeld P.J., Kaiser P.K., Ying G., Sun X., Xu X.; PHOENIX Study Group. Conbercept for Treatment of Neovascular Age-related Macular Degeneration: Results of the Randomized Phase 3 PHOENIX Study. Am J Ophthalmol. 2019;197:156–167. DOI: 10.1016/j.ajo.2018.08.026Liu K., Song Y., Xu G., Ye J., Wu Z., Liu X., Dong X., Zhang M., Xing Y., Zhu S., Chen X., Shen Y., Huang H., Yu L., Ke Z., Rosenfeld P.J., Kaiser P.K., Ying G., Sun X., Xu X.; PHOENIX Study Group. Conbercept for Treatment of Neovascular Age-related Macular Degeneration: Results of the Randomized Phase 3 PHOENIX Study. Am J Ophthalmol. 2019;197:156–167. DOI: 10.1016/j.ajo.2018.08.026Mettu P.S. What might the future of wet AMD therapy look like? Retina Today. The Neovascular AMD Pipeline. 2019;14(80):25–28.Mettu P.S. What might the future of wet AMD therapy look like? Retina Today. The Neovascular AMD Pipeline. 2019;14(80):25–28.Sadiq M.A., Hanout M., Sarwar S., Hassan M., Do D.V., Nguyen Q.D., Sepah Y.J. Platelet derived growth factor inhibitors: A potential therapeutic approach for ocular neovascularization. Saudi J Ophthalmol. 2015;29(4):287–291. DOI: 10.1016/j.sjopt.2015.05.005Sadiq M.A., Hanout M., Sarwar S., Hassan M., Do D.V., Nguyen Q.D., Sepah Y.J. Platelet derived growth factor inhibitors: A potential therapeutic approach for ocular neovascularization. Saudi J Ophthalmol. 2015;29(4):287–291. DOI: 10.1016/j.sjopt.2015.05.005Jaffe G.J., Ciulla T.A., Ciardella A.P., Devin F., Dugel P.U., Eandi C.M., Masonson H., Monés J., Pearlman J.A., Quaranta-E.l. Maftouhi M., Ricci F., Westby K., Patel S.C. Dual Antagonism of PDGF and VEGF in Neovascular Age-Related Macular Degeneration: A Phase IIb, Multicenter, Randomized Controlled Trial. Ophthalmology. 2017;124(2):224–234. DOI: 10.1016/j.ophtha.2016.10.010Jaffe G.J., Ciulla T.A., Ciardella A.P., Devin F., Dugel P.U., Eandi C.M., Masonson H., Monés J., Pearlman J.A., Quaranta-E.l. Maftouhi M., Ricci F., Westby K., Patel S.C. Dual Antagonism of PDGF and VEGF in Neovascular Age-Related Macular Degeneration: A Phase IIb, Multicenter, Randomized Controlled Trial. Ophthalmology. 2017;124(2):224–234. DOI: 10.1016/j.ophtha.2016.10.010Dunn E.N., Hariprasad S.M., Sheth V.S. An Overview of the Fovista and Rinucumab Trials and the Fate of Anti-PDGF Medications. Ophthalmic Surg Lasers Imaging Retina. 2017;48(2):100–104. DOI: 10.3928/23258160-20170130-02Dunn E.N., Hariprasad S.M., Sheth V.S. An Overview of the Fovista and Rinucumab Trials and the Fate of Anti-PDGF Medications. Ophthalmic Surg Lasers Imaging Retina. 2017;48(2):100–104. DOI: 10.3928/23258160-20170130-02Hussain R.M., Neiweem A.E., Kansara V., Harris A., Ciulla T.A. Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease. Expert Opinion on Investigational Drugs. 2019;28(10):861–869. DOI: 10.1080/13543784.2019.1667333Hussain R.M., Neiweem A.E., Kansara V., Harris A., Ciulla T.A. Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease. Expert Opinion on Investigational Drugs. 2019;28(10):861–869. DOI: 10.1080/13543784.2019.1667333Helzner J. Eylea/Ang2 Combo Disappoints in Phase 2. Retinal Physician. 2017; Nov/Dec.Helzner J. Eylea/Ang2 Combo Disappoints in Phase 2. Retinal Physician. 2017; Nov/Dec.Helzner J. Faricimab Shows Potential for 16-Week Dosing Initial data presented from Genentech’s STAIRWAY study. Retinal Physician. 2018; Sep.Helzner J. Faricimab Shows Potential for 16-Week Dosing Initial data presented from Genentech’s STAIRWAY study. Retinal Physician. 2018; Sep.Danzig С., Ruiz C., Basu K., Grzeschik S., Sahni J., Silverman D., Osborne A., Haskova Z. Efficacy and Safety of Faricimab Every 16 or 12 Weeks for Neovascular Age-Related Macular Degeneration: STAIRWAY Phase 2 Results. Presented at the Association for Research in Vision and Ophthalmology Vancouver, BC, Canada. April 28–May 2, 2019.Danzig С., Ruiz C., Basu K., Grzeschik S., Sahni J., Silverman D., Osborne A., Haskova Z. Efficacy and Safety of Faricimab Every 16 or 12 Weeks for Neovascular Age-Related Macular Degeneration: STAIRWAY Phase 2 Results. Presented at the Association for Research in Vision and Ophthalmology Vancouver, BC, Canada. April 28–May 2, 2019.Al-Khersan H., Hussain R.M., Ciulla T.A., Dugel P.U. Innovative therapies for neovascular age-related macular degeneration. Expert Opin Pharmacother. 2019;20(15):1879–1891. DOI: 10.1080/14656566.2019.1636031Al-Khersan H., Hussain R.M., Ciulla T.A., Dugel P.U. Innovative therapies for neovascular age-related macular degeneration. Expert Opin Pharmacother. 2019;20(15):1879–1891. DOI: 10.1080/14656566.2019.1636031Csaky K.G., Dugel P.U., Pierce A.J., Fries M.A., Kelly D.S., Danis R.P., Wurzelmann J.I., Xu C.F., Hossain M., Trivedi T. Clinical evaluation of pazopanib eye drops versus ranibizumab intravitreal injections in subjects with neovascular age-related macular degeneration. Ophthalmology. 2015;122(3):579–588. DOI: 10.1016/j.ophtha.2014.09.036Csaky K.G., Dugel P.U., Pierce A.J., Fries M.A., Kelly D.S., Danis R.P., Wurzelmann J.I., Xu C.F., Hossain M., Trivedi T. Clinical evaluation of pazopanib eye drops versus ranibizumab intravitreal injections in subjects with neovascular age-related macular degeneration. Ophthalmology. 2015;122(3):579–588. DOI: 10.1016/j.ophtha.2014.09.036Helzner J. Squalamine Eye Drop Fails in Wet AMD. Retinal Physician. 2018; Jan/Feb.Helzner J. Squalamine Eye Drop Fails in Wet AMD. Retinal Physician. 2018; Jan/Feb.Joussen A.M., Wolf S., Kaiser P.K., Boyer D., Schmelter T., Sandbrink R., Zeitz O., Deeg G., Richter A., Zimmermann T., Hoechel J., Buetehorn U., Schmitt W., Stemper B., Boettger M.K. The Developing Regorafenib Eye drops for neovascular Agerelated Macular degeneration (DREAM) study: an open-label phase II trial. Br J Clin Pharmacol. 2019;85(2):347–355. DOI: 10.1111/bcp.13794Joussen A.M., Wolf S., Kaiser P.K., Boyer D., Schmelter T., Sandbrink R., Zeitz O., Deeg G., Richter A., Zimmermann T., Hoechel J., Buetehorn U., Schmitt W., Stemper B., Boettger M.K. The Developing Regorafenib Eye drops for neovascular Agerelated Macular degeneration (DREAM) study: an open-label phase II trial. Br J Clin Pharmacol. 2019;85(2):347–355. DOI: 10.1111/bcp.13794Helzner J. Intravitreal Pan-VEGF Inhibitor Effective in Wet AMD Trial. Retinal Physician. 2019; Jan/Feb.Helzner J. Intravitreal Pan-VEGF Inhibitor Effective in Wet AMD Trial. Retinal Physician. 2019; Jan/Feb.

The authors declare that there are no conflicts of interest present.